Sir Henry Wellcome Laboratories, University of Southampton Medical School, Southampton General Hospital, Southampton, UK.
J Antimicrob Chemother. 2012 May;67(5):1145-54. doi: 10.1093/jac/dks031. Epub 2012 Feb 14.
In this study, the objective was to determine the anti-inflammatory properties of CyP, a cyanobacterial lipopolysaccharide (LPS) antagonist, used in combination with antibiotic chemotherapy during infection of an in vitro meningitis model infected with Neisseria meningitidis (meningococcus).
Monocultures of human meningioma cells and meningioma-primary human macrophage co-cultures were infected with meningococci (10(2)-10(8) cfu/monolayer) or treated with isolated outer membranes or purified LPS (0.1-100 ng/monolayer) from N. meningitidis. CyP (1-20 μg/monolayer) was added at intervals from t = 0 to 4 h, with and without benzylpenicillin (1-20 μg/monolayer). The antagonistic effect of CyP and its adjunctive properties to benzylpenicillin administration was determined by measuring cytokine levels in culture supernatants after 24 h.
CyP significantly inhibited (P < 0.05) the secretion of interleukin (IL)-6, IL-8, monocyte chemoattractant protein (MCP)-1 and RANTES ('regulated upon activation, normal T cell expressed and secreted') (overall reduction levels from 50% to >95%) by meningioma cell lines and meningioma-macrophage co-cultures challenged with either live meningococci or bacterial components. Inhibition was effective when CyP was added within 2 h of challenge (P < 0.05) and was still pronounced by 4 h. In the co-culture model, CyP alone partially inhibited IL-1β secretion, but did not prevent tumour necrosis factor (TNF)-α secretion, whereas penicillin alone inhibited IL-1β and TNF-α but conversely did not reduce MCP-1 and RANTES secretion. However, coadministration of CyP and penicillin in both models had an additive effect and restored the overall inhibitory profile.
CyP inhibits cytokine production in an in vitro meningitis model and augments the anti-inflammatory response when combined with benzylpenicillin. Administration of an LPS antagonist with antibiotic merits consideration in the emergency treatment of patients presenting with meningococcal infection.
本研究旨在确定 CyP 的抗炎特性,CyP 是一种蓝藻脂多糖 (LPS) 拮抗剂,在体外脑膜炎模型中与抗生素化疗联合使用,以治疗感染奈瑟脑膜炎球菌 (脑膜炎球菌) 的脑膜炎。
将人脑膜瘤细胞和脑膜瘤原代人巨噬细胞共培养物的单核培养物用脑膜炎球菌 (10(2)-10(8)cfu/单层) 感染或用分离的外膜或纯化的来自脑膜炎奈瑟氏菌的 LPS(0.1-100ng/单层)处理。CyP(1-20μg/单层)在 t=0 至 4 h 之间加入,有无苄青霉素 (1-20μg/单层)。通过测量 24 小时后培养上清液中的细胞因子水平来确定 CyP 的拮抗作用及其与苄青霉素给药的附加特性。
CyP 显著抑制 (P<0.05) 脑膜瘤细胞系和脑膜瘤-巨噬细胞共培养物中由活脑膜炎球菌或细菌成分刺激的白细胞介素 (IL)-6、IL-8、单核细胞趋化蛋白 (MCP)-1 和 RANTES('激活后调节,正常 T 细胞表达和分泌') 的分泌 (总体减少水平为 50%至>95%)。当 CyP 在挑战后 2 小时内加入时,抑制作用有效 (P<0.05),4 小时后仍明显。在共培养模型中,CyP 单独部分抑制 IL-1β 的分泌,但不能防止肿瘤坏死因子 (TNF)-α的分泌,而单独使用青霉素抑制 IL-1β 和 TNF-α,但相反不减少 MCP-1 和 RANTES 的分泌。然而,在两种模型中联合使用 CyP 和青霉素具有相加作用,并恢复了总体抑制谱。
CyP 抑制体外脑膜炎模型中的细胞因子产生,并与苄青霉素联合使用时增强抗炎反应。在出现脑膜炎球菌感染的患者的紧急治疗中,给予 LPS 拮抗剂与抗生素联合使用是值得考虑的。